Emmanuel S Antonarakis1, Charles G Drake. 1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA.
Abstract
PURPOSE OF REVIEW: The autologous antigen-presenting cell immunotherapy, sipuleucel-T, was the first and remains the only US Food and Drug Administration-approved immunotherapy for prostate cancer. In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials. RECENT FINDINGS: Multiple studies are now testing sipuleucel-T in different disease settings and/or in combination with conventional and novel hormonal therapies. In addition, a poxviral-based vaccine has shown promise in early-phase clinical studies and has now entered phase 3 testing in men with metastatic prostate cancer. Next, a DNA vaccine has been evaluated in men with biochemically recurrent prostate cancer and has shown early signs of clinical efficacy. Finally, several studies are evaluating the role of immune checkpoint blockade using ipilimumab in pivotal phase 3 trials in prostate cancer patients with advanced disease, as well as in earlier phase studies in combination with androgen ablation. SUMMARY: The abundance of new treatment options for men with advanced prostate cancer will challenge the role of immunotherapy in these patients. Future progress may rely on optimal combination and sequencing of various immunotherapies with androgen-directed approaches as well as with other standard prostate cancer therapies, an effort which is now just beginning.
PURPOSE OF REVIEW: The autologous antigen-presenting cell immunotherapy, sipuleucel-T, was the first and remains the only US Food and Drug Administration-approved immunotherapy for prostate cancer. In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials. RECENT FINDINGS: Multiple studies are now testing sipuleucel-T in different disease settings and/or in combination with conventional and novel hormonal therapies. In addition, a poxviral-based vaccine has shown promise in early-phase clinical studies and has now entered phase 3 testing in men with metastatic prostate cancer. Next, a DNA vaccine has been evaluated in men with biochemically recurrent prostate cancer and has shown early signs of clinical efficacy. Finally, several studies are evaluating the role of immune checkpoint blockade using ipilimumab in pivotal phase 3 trials in prostate cancerpatients with advanced disease, as well as in earlier phase studies in combination with androgen ablation. SUMMARY: The abundance of new treatment options for men with advanced prostate cancer will challenge the role of immunotherapy in these patients. Future progress may rely on optimal combination and sequencing of various immunotherapies with androgen-directed approaches as well as with other standard prostate cancer therapies, an effort which is now just beginning.
Authors: Neil H Bander; Matthew I Milowsky; David M Nanus; Lale Kostakoglu; Shankar Vallabhajosula; Stanley J Goldsmith Journal: J Clin Oncol Date: 2005-04-18 Impact factor: 44.544
Authors: M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon Journal: Proc Natl Acad Sci U S A Date: 2001-12-04 Impact factor: 11.205
Authors: Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler Journal: Cancer Cell Date: 2005-03 Impact factor: 31.743
Authors: Emmanuel S Antonarakis; Zhaoyong Feng; Bruce J Trock; Elizabeth B Humphreys; Michael A Carducci; Alan W Partin; Patrick C Walsh; Mario A Eisenberger Journal: BJU Int Date: 2011-07-20 Impact factor: 5.588
Authors: Lawrence Fong; Serena S Kwek; Shaun O'Brien; Brian Kavanagh; Douglas G McNeel; Vivian Weinberg; Amy M Lin; Jonathan Rosenberg; Charles J Ryan; Brian I Rini; Eric J Small Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: Ravi A Madan; James L Gulley; Jeffrey Schlom; Seth M Steinberg; David J Liewehr; William L Dahut; Philip M Arlen Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag C Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Oyvind S Bruland Journal: Lancet Oncol Date: 2007-07 Impact factor: 41.316
Authors: C Sanchez; R Chan; P Bajgain; S Rambally; G Palapattu; M Mims; C M Rooney; A M Leen; M K Brenner; J F Vera Journal: Prostate Cancer Prostatic Dis Date: 2013-01-08 Impact factor: 5.554